Literature DB >> 34480476

Cerebrospinal Fluid Pathologies in Schizophrenia-Spectrum Disorder-A Retrospective Chart Review.

Mattia Campana1, Johanna Strauß1, Susanne Münz1, Tatiana Oviedo-Salcedo1, Piyumi Fernando2, Peter Eichhorn3, Peter Falkai1, Alkomiet Hasan2, Elias Wagner1.   

Abstract

BACKGROUND: The role of inflammatory processes in the etiology of schizophrenia is increasingly being investigated. A link between psychosis and inflammation measured with different biomarkers has been reported in the literature and needs to be further explored. To investigate the presence of inflammatory biomarkers in first-episode psychosis (FEP) we analyzed the largest available FEP cohort to date regarding routine CSF and blood diagnostics.
METHODS: We report a retrospective analysis of clinical data from all inpatients that were admitted to our tertiary care hospital with a ICD-10 diagnosis of F2x (schizophrenia-spectrum) between January 1, 2008 and August 1, 2018 and underwent a lumbar puncture.
RESULTS: A total of n = 314 FEP patients were included in our sample. 42.7% patients (134/314) showed cerebrospinal fluid (CSF) alterations. Oligoclonal bands in the CSF were present in 21.8% of patients (67/307) with 12.4% (27/217) of patients presenting OCBs type 2 or 3. 15.8% (49/310) of our cohort revealed signs of blood-brain-barrier (BBB) dysfunction with increased albumin ratios. Mean serum CRP levels were 2.4 mg/l (SD = 9.5). CRP elevation was present in 116/280 cases (41.4%).
CONCLUSIONS: This large retrospective analysis on FEP cohort greatly enriches the clinical data available on this population and contributes to the discussion around inflammation in psychosis. Of note, even though several inflammatory alterations were found both in CSF and in blood tests, we found no evidence for a significant relationship between peripheral inflammation and inflammatory CSF. Furthermore, no significant relationship between CSF alterations and peripheral inflammation measured with CRP could be established.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CSF; blood-brain-barrier; first-episode psychosis; inflammation; schizophrenia

Mesh:

Year:  2022        PMID: 34480476      PMCID: PMC8781327          DOI: 10.1093/schbul/sbab105

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   7.348


  31 in total

1.  Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls.

Authors:  S Haghighi; O Andersen; L Rosengren; T Bergström; J Wahlström; S Nilsson
Journal:  J Neurol       Date:  2000-08       Impact factor: 4.849

2.  Serum oligoclonal IgG is a common and persistent finding in multiple sclerosis, and has a systemic source.

Authors:  A Z Zeman; G Keir; R Luxton; E J Thompson
Journal:  QJM       Date:  1996-03

3.  Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production.

Authors:  K Blennow; P Fredman; A Wallin; C G Gottfries; I Skoog; C Wikkelsö; L Svennerholm
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

Review 4.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

5.  Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.

Authors:  Michael E Benros; Berit L Waltoft; Merete Nordentoft; Søren D Ostergaard; William W Eaton; Jesper Krogh; Preben B Mortensen
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

6.  Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction.

Authors:  K Bechter; H Reiber; S Herzog; D Fuchs; H Tumani; H G Maxeiner
Journal:  J Psychiatr Res       Date:  2009-09-30       Impact factor: 4.791

7.  Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis.

Authors:  Sonja Orlovska-Waast; Ole Köhler-Forsberg; Sophie Wiben Brix; Merete Nordentoft; Daniel Kondziella; Jesper Krogh; Michael Eriksen Benros
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

8.  Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis.

Authors:  Dominique Endres; Sophie Meixensberger; Harald Prüss; Ludger Tebartz van Elst; Rick Dersch; Bernd Feige; Oliver Stich; Nils Venhoff; Miriam Matysik; Simon J Maier; Maike Michel; Kimon Runge; Kathrin Nickel; Horst Urbach; Katharina Domschke
Journal:  Transl Psychiatry       Date:  2020-08-12       Impact factor: 6.222

9.  Time for a change of practice: the real-world value of testing for neuronal autoantibodies in acute first-episode psychosis.

Authors:  Thomas A Pollak; Belinda R Lennox
Journal:  BJPsych Open       Date:  2018-07-16
View more
  1 in total

Review 1.  Immunopsychiatry - Innovative Technology to Characterize Disease Activity in Autoantibody-Associated Psychiatric Diseases.

Authors:  Niels Hansen
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.